Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi(University of Colorado Denver), Marzia Capelletti(Dana-Farber Cancer Institute), Anh T. Le(University of Colorado Denver), Severine Kako(University of Colorado Cancer Center), Mohit Butaney(Dana-Farber Cancer Institute), Dalia Ercan(Dana-Farber Cancer Institute), Sakshi Mahale(University of Colorado Cancer Center), Kurtis D. Davies(University of Colorado Denver), Dara L. Aisner(University of Colorado Cancer Center), Amanda Pilling(University of Colorado Denver), Eamon M. Berge(University of Colorado Denver), Jhingook Kim(Samsung Medical Center), Hidefumi Sasaki(Nagoya City University), Seung-Il Park(Ulsan College), Gregory V. Kryukov(Broad Institute), Levi A. Garraway(Broad Institute), Peter S. Hammerman(Dana-Farber Cancer Institute), Julia Haas(Array BioPharma (United States)), Steven W. Andrews(Array BioPharma (United States)), Doron Lipson(Boston Foundation), Philip J. Stephens(Boston Foundation), Vince A Miller(Boston Foundation), Marileila Varella‐Garcia(University of Colorado Cancer Center), Pasi A. Jänne(Dana-Farber Cancer Institute), Robert C. Doebele(University of Colorado Cancer Center)
Cited by 602Open Access